This trial is active, not recruiting.

Conditions deep vein thrombosis, coronary artery bypass surgery, venous thromboembolism
Treatments fondaparinux, placebo
Sponsor Prairie Education and Research Cooperative
Collaborator American College of Phlebology
Start date October 2009
End date December 2015
Trial size 630 participants
Trial identifier NCT00789399, 00508826


This trial is a prospective, single-center Phase II randomized study to demonstrate the superior efficacy of Fondaparinux Sodium subcutaneous injections in patients undergoing CABG surgery (isolated and redo isolated) versus treatment with placebo. All consecutive patients scheduled for CABG surgery that meet the general inclusion and none of the exclusion criteria will be considered for enrollment in the study.

Consecutive patients will be randomized on the day of admission prior to their CABG surgery into one of two groups. One group will be randomized to the placebo while the second group will receive 2.5 mg Fondaparinux Sodium injections. Both groups will receive routine mechanical prophylaxis as determined by the treating physicians. Group randomized to receive Fondaparinux Sodium will receive a 2.5 mg SQ daily drug dose starting 12 +/- 2 hours post-wound closure or the following day in the morning (at the discretion of the cardiothoracic surgeon). The second dose would be administered 24 hours later and the dosing will then be once a day. The group randomized to placebo will receive subcutaneous equivolume isotonic saline at the same time points described above.

Patients randomized will receive a 2.5 mg dose of Fondaparinux Sodium or placebo subcutaneously for a total of 3-9 days post CABG with day 1 being the day of surgery. The drug will be discontinued if the patient is discharged before day 9. If the patient stays for more than 9 days inside hospital, a duplex would be obtained per protocol and further DVT prevention measures would be instituted per the discretion of treating physician.

Patients will be assessed daily while hospitalized for any symptoms and adverse reactions and will undergo laboratory testing (CBC, PT/INR, PTT and UA) as specified in the protocol. Post-op day 3-9(no later than 2 days after the last preventive drug dose) patients will undergo the protocol specific lower limb venous duplex scan and earlier if symptomatic. Patients will also be contacted (phone/office visit) for follow-up 25-35 days post CABG to assess for signs or symptoms of deep venous thrombosis or thromboembolism and for any potential complications.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
(Active Comparator)
Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
fondaparinux DVT
Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
(Placebo Comparator)
placebo DVT
subcutaneous equivolume isotonic saline

Primary Outcomes

Rate of asymptomatic proximal DVT
time frame: 7 days

Secondary Outcomes

Asymptomatic Distal DVT
time frame: 7 days

Eligibility Criteria

Male or female participants from 18 years up to 90 years old.

Subject Inclusion Criteria In order to be enrolled in the study, subjects must meet all of the inclusion criteria as listed below. 1. Consecutive patients undergoing isolated or redo isolated CABG 2. Patients must provide written informed consent 3. Patients must agree to comply with study procedures for the entire length of the study. 4. Must be 18 years old or greater. Subject Exclusion Criteria Any subject that meets any of the exclusion criteria listed below at baseline will be excluded from study participation. 1. Patients with medical history that requires chronic anticoagulation with unfractionated heparin or coumadin or LMWH or heparinoids (i.e. previous DVT, pulmonary embolism, atrial fibrillation, heart valve replacement) 2. Patients with contraindications to anticoagulation (coagulopathy e.g, INR>/=1.5, generalized bleeding disorders, peptic ulcer disease, hemorrhagic or ischemic stroke, etc within last 3 months) 3. Patients who are unable to undergo a doppler ultrasound of the lower extremities 4. Renal insufficiency (creatinine clearance < 30 mL/min) 5. Patients who have a body weight < 50 kg 6. Patients receiving continuous (indwelling) epidural 7. Physician diagnosed acute or chronic hepatic failure 8. Pregnancy 9. Patients with life expectancy < 6 months 10. Platelet count below 100,000/ mm-3 11. History of documented VTE within last 3 months. 12. Acute bacterial endocarditis 13. Cerebral metastasis or abscess 14. Inability to consent 15. Refusal by treating physician

Additional Information

Official title A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis
Description Background Information Venous thromboembolism (VTE) following coronary artery bypass graft (CABG) surgery is a formidable risk in view of various predisposing factors including restriction of activity, history of myocardial infarctions in such patients, presence of multiple predisposing baseline demographic characteristics and risk factors including advanced age and smoking. The reported incidence of asymptomatic deep vein thrombosis (DVT) using duplex ultrasound (DUS) is significant and varies from 16 to 48%, most of the thrombi being calf vein. (1,2,3) The incidence of symptomatic VTE based chiefly on retrospective data ranges from 0.5 to 3.9% for VTE, 0.3 to 0.5% for DVT, 0.2 to 3.9% for PE, and 0.06 to 0.7% for fatal PE. (2-10)The absolute number of affected patients may be significant since the number of such procedures performed every year in the US alone is huge. According to the American Heart Association's Heart Disease and Stroke Statistics - 2008 Update, 469,000 surgical revascularizations were done in the US in 2005. The benefits of thromboprophylaxis in medically ill patients including those with congestive heart failure have been well demonstrated with up to 60% reduction in VTE risk. (11) The patients who undergo CABG have similar risk profiles and hence should be evaluated with pharmacokinetic thromboprophylacic strategy. In CABG patients, the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), 2008, (12) does recommend routine prophylaxis with low molecular weight heparin (LMWH), low dose unfractionated heparin (LDUH), or optimally used bilateral graduated compression stockings (GCS) or intermittent pneumatic compression (IPC). The guidelines are based on moderate to low quality evidence and the strength of these recommendations is weak as there have been no randomized controlled trials. Rationale In CABG patients, the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), 2008,(12) recommend routine prophylaxis with LMWH, LDUH, or optimally used bilateral GCS or IPC. The guidelines are based on moderate to low quality evidence and the strength of the recommendation is weak as there have been no randomized controlled trials. Optimally used stockings may not be applicable to many CABG patients because of saphenous vein harvesting and hence pharmacologic means are preferable. Fondaparinux is a pentasaccharide with an efficacy and safeties shown to be equal to or better than LMWH and thus may be a preferred agent for VTE prophylaxis. (13-18) OBJECTIVES The primary goal of this study is to demonstrate the superiority of Fondaparinux Sodium over placebo for the prevention of VTE in Patients undergoing Coronary Bypass Graft Surgery (CABG). Primary Efficacy Endpoint: • Cumulative incidence of all VTE (defined as symptomatic and asymptomatic deep-vein thrombosis, fatal and non-fatal pulmonary embolism, or both) up to day 11 Secondary Efficacy Endpoints: • Primary efficacy end-point and VTE up to day 35 Primary Safety Endpoints: • Major bleeding event up to day 11 Secondary Safety Endpoints: - Cumulative major and minor bleeding event up to day 11 - Deaths, requirement of transfusions and other adverse events up to day 35 STUDY DESIGN This trial is a phase II, prospective, single-center, assessor and patient-blinded, placebo controlled, randomized study to demonstrate the superior thromboprophylactic efficacy of Fondaparinux Sodium subcutaneous injections in patients undergoing CABG surgery versus placebo. OBJECTIVES The primary efficacy objectives include an assessment of the cumulative rate of all VTE (defined as DVT or fatal or non-fatal pulmonary embolism or both) up to 11 days post CABG. The primary safety objectives include the assessment of the frequency and occurrence of all major bleeding events post-operatively up to day 3-11. Finally, the secondary efficacy objective will include cumulative VTE events and assessment of the components of VTE while the secondary safety objective will include an assessment of the frequency of non-major bleeding events up to day 3-11 as well as all cause deaths, need for transfusion and other monitored adverse events till day 35. The inclusion of safety is mainly for descriptive purposes because the study is not be powered for safety end points. The safety and efficacy endpoints will determine Fondaparinux Sodium's ability over placebo to prevent VTE while assessing the bleeding risk in this study population. A randomized control is needed because a head to head comparison of Fondaparinux Sodium and placebo is being planned. Approximate time to complete study enrollment is 2 years. This estimation is based on the number of subjects needed for the study and the rate of CABG surgery performed at the institution.
Trial information was received from ClinicalTrials.gov and was last updated in October 2014.
Information provided to ClinicalTrials.gov by Prairie Education and Research Cooperative.